MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Thrombosis and Haemostasis Année : 2013

MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs

Xavier Leleu
  • Fonction : Auteur
Philippe Rodon
  • Fonction : Auteur
Laurent Daley
  • Fonction : Auteur
Jean-Claude Eisemann
  • Fonction : Auteur
Olivier Fitoussi
  • Fonction : Auteur
Borhane Slama
  • Fonction : Auteur
Ahmad Al Jijakli
  • Fonction : Auteur
Riad Benramdane
  • Fonction : Auteur
Carinne Chaleteix
  • Fonction : Auteur
Régis Costello
  • Fonction : Auteur
Antoine Thyss
  • Fonction : Auteur
Eileen Boyle
  • Fonction : Auteur
Anne-Marie Stoppa
  • Fonction : Auteur
Anne Lamblin
  • Fonction : Auteur
Patrick Natta
  • Fonction : Auteur
Philippe Moreau
  • Fonction : Auteur
  • PersonId : 842727

Résumé

Immunomodulatory drugs (IMiDs) are associated with an increased risk of venous thromboembolism (VTE) in multiple myeloma (MM) patients. We designed MELISSE, a multicentre prospective observational study, to evaluate VTE incidence and identify risk factors in IMiDs-treated MM. Our objective was to determine the real-life practice of VTE prophylaxis strategy. A total of 524 MM patients were included, and we planned to collect information at baseline, at four and at 12 months, on MM therapy, on VTE risk factors and management. VTE incidence was 7% (n=31), including 2.5% pulmonary embolism (PE) (n=11), similar at four or 12 months. VTE was observed at all risk assessment levels, although the increased risk assessment level correlated to a lower rate of VTE, maybe due to the implemented thromboprophylaxis strategy. VTE occurred in 7% on aspirin vs 3% on low-molecular-weight heparin (LMWH) prophylaxis, and none on vitamin K antagonists (VKA). New risk factors for VTE in IMiDs-treated MM were identified. In conclusion, VTE prophylaxis is compulsory in IMiDs-treated MM, based on individualised VTE risk assessment. Anticoagulation prophylaxis with LMWH should clearly be prioritised in MM patients with high VTE risk, along with VKA. Further prospective studies will identify most relevant VTE risk factors in IMiDs-treated MM to select accurately which MM patients should receive LMWH prophylaxis and for which duration to optimise VTE risk reduction.
Fichier non déposé

Dates et versions

hal-01064326 , version 1 (16-09-2014)

Identifiants

Citer

Xavier Leleu, Philippe Rodon, Cyrille Hulin, Laurent Daley, Charles Dauriac, et al.. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. Thrombosis and Haemostasis, 2013, 110 (4), pp.844--851. ⟨10.1160/TH13-02-0140⟩. ⟨hal-01064326⟩
290 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More